Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Reply to Paolo Zaurito’s Letter to the Editor re: Robert M. Meier, Nima Aghdam, Alan C. Beckman, et al. 10-yr Survival and Toxicity Outcomes of Stereotactic Body Radiotherapy for Prostate Cancer: A Nonrandomized Clinical Trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.04.029. Local targets link to admitted publications; unresolved targets remain external evidence.
Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer
10.1056/nejmoa2214122 · 2023 · External reference
10.1016/j.eururo.2026.06.009
10.1016/j.eururo.2026.06.009 · External reference
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?
10.1016/s0022-5347(05)66452-x · 2001 · External reference
Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer
10.1056/nejmoa2403365 · 2024 · External reference
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
10.1016/s0140-6736(19)31131-6 · 2019 · External reference
Exploring factors associated with late urinary toxicity after prostate stereotactic body radiotherapy: findings from the PACE-B study
10.1016/j.eururo.2025.07.007 · 2026 · External reference
Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score
10.1111/bju.16927 · 2026 · External reference
Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial
10.1016/j.eururo.2024.08.030 · 2024 · External reference
